{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T13:04:44Z","timestamp":1777640684893,"version":"3.51.4"},"reference-count":18,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Respir Dis"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Afatinib is indicated for patients with advanced-stage non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations, including uncommon mutations. However, the differences in survival benefits between patients with different types of EGFR mutations remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>This study aimed to compare the effectiveness of afatinib treatment in patients harboring the EGFR-G719X mutation with that in patients carrying other uncommon EGFR mutations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>This was a retrospective study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Ninety-two patients with locally advanced and metastatic NSCLC, of whom 49 patients with EGFR-G719X mutations that were both single and compound, and 43 patients harbored other uncommon EGFR mutations, who were treated with afatinib as first-line treatment. The patients were followed up and evaluated every 3\u2009months or when there were symptoms of progressive disease. The endpoints were the objective response rate (ORR), time-to-treatment failure (TTF), and overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The average ages of patients with the EGFR-G719X and uncommon EGFR mutations were 62.7\u2009years and 63.1\u2009years, respectively. There were no significant differences in sex or smoking history between the two groups. In total, 28.6% of patients with the G719X mutation and 23.3% of patients with other mutations had brain metastases. The ORR of patients with the G719X mutation was 79.6%, which was 10% higher than that of patients with other EGFR mutations. Patients harboring the EGFR-G719X mutation had median TTF and median OS periods of 19.3\u2009months and 31.4\u2009months, respectively, which were significantly higher than those of patients carrying other mutations at 11.2\u2009months. Subgroup analysis showed that TTF and OS benefits were observed in female patients, patients without brain metastasis, and patients with good performance status who harbored the G719X mutation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Patients with the EGFR-G719X mutation achieve significantly better TTF and OS benefits than those with other uncommon EGFR mutations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17534666251341747","type":"journal-article","created":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T02:38:54Z","timestamp":1748140734000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Excellent survival benefit achieved in patients with advanced-stage non-small cell lung cancer harboring the epidermal growth factor receptor-G719X mutation treated by afatinib: the real-world data from a multicenter study in Vietnam"],"prefix":"10.1177","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2291-1054","authenticated-orcid":false,"given":"Van Luan","family":"Pham","sequence":"first","affiliation":[{"name":"Military Central Hospital 108, Hanoi, Vietnam"},{"name":"College of Health Sciences, VinUniversity, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4342-0959","authenticated-orcid":false,"given":"Cam Phuong","family":"Pham","sequence":"additional","affiliation":[{"name":"Hanoi Medical University, Hanoi, Vietnam"},{"name":"Bach Mai Hospital, Giai Phong, Hanoi, Vietnam"},{"name":"University of Medicine and Pharmacy, Vietnam National University, Hanoi, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thi Thai Hoa","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Vietnam National Cancer Hospital, Hanoi, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuan Khoi","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Ho Chi Minh City Oncology Hospital, Ho Chi Minh, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minh Hai","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Military Central Hospital 108, Hanoi, Vietnam"},{"name":"College of Health Sciences, VinUniversity, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thi Anh Thu","family":"Hoang","sequence":"additional","affiliation":[{"name":"Ho Chi Minh City Oncology Hospital, Ho Chi Minh, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuan Anh","family":"Le","sequence":"additional","affiliation":[{"name":"Cho Ray Hospital, Ho Chi Minh, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8313-5688","authenticated-orcid":false,"given":"Dinh Thy Hao","family":"Vuong","sequence":"additional","affiliation":[{"name":"Cho Ray Hospital, Ho Chi Minh, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dac Nhan Tam","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Thong Nhat Hospital, Ho Chi Minh, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Van Khiem","family":"Dang","sequence":"additional","affiliation":[{"name":"National Lung Hospital, Hanoi, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thi Oanh","family":"Nguyen","sequence":"additional","affiliation":[{"name":"National Lung Hospital, Hanoi, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6059-7046","authenticated-orcid":false,"given":"Hung Kien","family":"Do","sequence":"additional","affiliation":[{"name":"Vietnam National Cancer Hospital, Hanoi, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3585-8460","authenticated-orcid":false,"given":"Ha Thanh","family":"Vu","sequence":"additional","affiliation":[{"name":"Vietnam National Cancer Hospital, Hanoi, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thi Thuy Hang","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Vietnam National Cancer Hospital, Hanoi, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3073-8406","authenticated-orcid":false,"given":"Van Thai","family":"Pham","sequence":"additional","affiliation":[{"name":"Hanoi Medical University, Hanoi, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Le Huy","family":"Trinh","sequence":"additional","affiliation":[{"name":"Hanoi Medical University, Hanoi, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6759-9683","authenticated-orcid":false,"given":"Hoang Gia","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Hanoi Oncology Hospital, Hanoi, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3953-6729","authenticated-orcid":false,"given":"Cong Minh","family":"Truong","sequence":"additional","affiliation":[{"name":"Vietnam National Cancer Hospital, Hanoi, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tran Minh Chau","family":"Pham","sequence":"additional","affiliation":[{"name":"Ho Chi Minh City Oncology Hospital, Ho Chi Minh, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thi Bich Phuong","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Vietnam National Cancer Hospital, Hanoi, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,5,24]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2013.147"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2019.04.12"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000504"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00026-1"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.06.007"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24386"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.10.004"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00931"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241242972"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_4_12_2","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). version 5.0; November 27 2017."},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39335.541782.AD"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.12.126"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-023-00946-w"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14156"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-4035"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03898-1"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3854"}],"container-title":["Therapeutic Advances in Respiratory Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17534666251341747","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17534666251341747","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17534666251341747","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T08:18:20Z","timestamp":1767687500000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17534666251341747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":18,"alternative-id":["10.1177\/17534666251341747"],"URL":"https:\/\/doi.org\/10.1177\/17534666251341747","relation":{"has-review":[{"id-type":"doi","id":"10.1177\/17534666251341747\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666251341747\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666251341747\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666251341747\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666251341747\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666251341747\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666251341747\/v3\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666251341747\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666251341747\/v2\/decision1","asserted-by":"object"}]},"ISSN":["1753-4666","1753-4666"],"issn-type":[{"value":"1753-4666","type":"print"},{"value":"1753-4666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"article-number":"17534666251341747"}}